The receipt of a notice of allowance for a patent application is a significant positive development for any biotech company, especially one focused on neurodegenerative diseases. It not only enhances the company's intellectual property portfolio but also increases its attractiveness to investors and potential partners. For Synaptogenix, this could lead to increased investor confidence, potentially driving up the stock price in the short term.